Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
FEMS Microbiol Ecol ; 92(7)2016 07.
Article in English | MEDLINE | ID: mdl-27162181

ABSTRACT

An altered immune response and gut microbiota have been associated with the pathology of inflammatory bowel diseases (IBDs). However, there is limited knowledge of how inflammation is associated with changes in the microbiota. We studied the microbiota in the intestine and faeces as well as the cytokine gene expressions in caecum and colon of a mouse model (Gαi2(-/-)) of colitis, and analysed them in relation to the degrees of inflammation in the colon. The degree of colitis was associated with general changes in the complexity of the microbiota and was corroborated by quantitative analyses of the Bacteroides and Lactobacillus High gene expression levels of IL-17 and IFN-γ in colon and caecum were detected in Gαi2(-/-) mice with moderate and severe colitis. High IL-27 gene expression in the colon of mice with moderate and severe colitis and in the caecum of mice with moderate colitis was also detected. Negative correlations between IL-27 and Bacteroides and Lactobacillus and between IFN-γ and Lactobacillus were detected in caecum. This research indicates that the degree of colitis in IBD correlates with the gene expression of cytokines and with disturbances in the gut microbiota. Furthermore, the caecum could have an important role in the pathology of IBD.


Subject(s)
Colitis/microbiology , Gastrointestinal Microbiome , Animals , Bacteria/classification , Bacteria/genetics , Bacteria/isolation & purification , Cecum/immunology , Cecum/microbiology , Cecum/pathology , Colitis/immunology , Colitis/pathology , Colon/immunology , Colon/microbiology , Cytokines/immunology , Humans , Interleukin-17/immunology , Intestines/immunology , Intestines/microbiology , Intestines/pathology , Mice , Mice, Knockout
2.
Scand J Gastroenterol ; 50(5): 528-35, 2015 May.
Article in English | MEDLINE | ID: mdl-25648657

ABSTRACT

OBJECTIVE: Patients who undergo ileal pouch-anal anastomosis (IPAA) after colectomy for ulcerative colitis (UC) occasionally have neoplasia in the IPAA. Patients with evidence of dysplasia or carcinoma in the colorectal specimen may have an increased risk of such neoplasia. A surveillance program has been suggested. The aims of this study were to evaluate the outcomes of surveillance of a large patient cohort, and to investigate the prevalences of neoplasia in the ileal pouch mucosa and in the anal transitional zone (ATZ). MATERIAL AND METHODS: A total of 629 patients underwent IPAA for UC at Sahlgrenska University Hospital, Gothenburg, Sweden. Identified from a register, 73 patients with neoplasia in their specimen considered eligible for the trial were prospectively enrolled, and underwent clinical examination, endoscopy with macroscopic evaluation, and mucosal biopsies from the ileal pouch and the ATZ. The biopsies were independently evaluated by two experienced gastro-pathologists. RESULTS: In all, 56 patients (39 males) with a median follow-up time of 18 (range, 1-29) years were evaluated. One patient (1.8%; 95% CI 0%-5.3%) showed low-grade dysplasia in the pouch, as recorded by one of the two pathologists. The individual pathologists recorded indefinite for dysplasia (IFD) in the pouch for 19 and 20 patients, respectively, and IFD in the ATZ for 2 and 4 patients, respectively. None of the biopsies showed evidence of high-grade dysplasia (HGD) or carcinoma. CONCLUSIONS: Neoplasia in the ileal pouch or ATZ after IPAA for UC is rare in the proposed risk group. The necessity for and value of a routine surveillance program should be prospectively evaluated.


Subject(s)
Anastomosis, Surgical/adverse effects , Carcinoma/pathology , Colitis, Ulcerative/pathology , Colonic Pouches/pathology , Proctocolectomy, Restorative/adverse effects , Adult , Aged , Anal Canal/pathology , Biopsy , Colitis, Ulcerative/surgery , Female , Follow-Up Studies , Humans , Ileum/pathology , Male , Middle Aged , Risk Factors , Sweden
3.
Int Immunol ; 25(1): 35-44, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22962436

ABSTRACT

Gαi2-deficient mice spontaneously develop colitis. Using xMAP technology and RT-PCR, we investigated cytokine/chemokine profiles during histologically defined phases of disease: (i) no/mild, (ii) moderate, (iii) severe colitis without dysplasia/cancer and (iv) severe colitis with dysplasia/cancer, compared with age-matched wild-type (WT) littermates. Colonic dysplasia was observed in 4/11 mice and cancer in 1/11 mice with severe colitis. The histology correlated with progressive increases in colon weight/cm and spleen weight, and decreased thymus weight, all more advanced in mice with dysplasia/cancer. IL-1ß, IL-6, IL-12p40, IL-17, TNF-α, CCL2 and CXCL1 protein levels in colons, but not small intestines increased with colitis progression and were significantly increased in mice with moderate and severe colitis compared with WT mice, irrespective of the absence/presence of dysplasia/cancer. CCL5 did not change during colitis progression. Colonic IL-17 transcription increased 40- to 70-fold in all stages of colitis, whereas IFN-γ mRNA was gradually up-regulated 12- to 55-fold with colitis progression, and further to 62-fold in mice with dysplasia/cancer. IL-27 mRNA increased 4- to 15-fold during the course of colitis, and colonic IL-21 transcription increased 3-fold in mice with severe colitis, both irrespective of the absence/presence of dysplasia/cancer. FoxP3 transcription was significantly enhanced (3.5-fold) in mice with moderate and severe colitis, but not in mice with dysplasia/cancer, compared with WT mice. Constrained correspondence analysis demonstrated an association between increased protein levels of TNF-α, CCL2, IL-1ß, IL-6 and CXCL1 and dysplasia/cancer. In conclusion, colonic responses are dominated by a mixed T(h)1/T(h)17 phenotype, with increasing T(h)1 cytokine transcription with progression of colitis in Gαi2(-/-) mice.


Subject(s)
Colitis/immunology , Colon/immunology , Colonic Neoplasms/immunology , Cytokines/immunology , GTP-Binding Protein alpha Subunit, Gi2/deficiency , Th1 Cells/immunology , Th17 Cells/immunology , Animals , Colitis/genetics , Colitis/metabolism , Colitis/pathology , Colon/pathology , Colonic Neoplasms/genetics , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Cytokines/genetics , Female , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/immunology , GTP-Binding Protein alpha Subunit, Gi2/genetics , GTP-Binding Protein alpha Subunit, Gi2/immunology , Gene Expression Regulation/immunology , Intestine, Small/immunology , Intestine, Small/pathology , Male , Mice , Mice, Knockout , Organ Size , Severity of Illness Index , Signal Transduction , Spleen/immunology , Spleen/pathology , Th1 Cells/metabolism , Th1 Cells/pathology , Th1-Th2 Balance , Th17 Cells/metabolism , Th17 Cells/pathology , Thymus Gland/immunology , Thymus Gland/pathology , Transcription, Genetic/immunology
4.
Anticancer Res ; 32(8): 3391-5, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22843920

ABSTRACT

A total of 2090 patients with endometrial carcinoma were followed-up for at least five years. The treatment modalities, as well as the results of treatment, regarding 272 patients with disease relapse are presented. The results are not encouraging. We found no statistically significant difference regarding overall survival, when the patients were divided according to initial stage or ploidy status. There was also no significant difference between overall survival and the mode of treatment. 108 out of 272 patients with relapse died of their disease. Regarding patients in stage I-II we present the survival for every studied year, where we compared those with more than one site of metastasis (n=108), more than one metastasis (n=59), or no relapse at all (n=1289) with an age-corrected Swedish female population. We found that the vast majority of patients did not die from their cancer-related illnesses, and also found an increased death-rate among those with cancer without relapse, compared to those without cancer (20% compared to 14%, 5 year follow-up). We conclude that the majority of patients would benefit from an increased effort to cure other illnesses rather than concentrating on cancer treatment alone.


Subject(s)
Carcinoma/mortality , Carcinoma/pathology , Endometrial Neoplasms/mortality , Endometrial Neoplasms/pathology , Carcinoma/therapy , Endometrial Neoplasms/therapy , Female , Follow-Up Studies , Humans , Ploidies , Recurrence , Sweden/epidemiology
5.
Anticancer Res ; 32(4): 1443-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22493383

ABSTRACT

AIM: The aims of this study were i) to assess a new and more detailed histopathological classification and to analyze concordance between pathologists in the histopathological classification of pseudomyxoma peritonei (PMP); ii) to analyze the expression in the stroma of the particularly interesting new cysteine-histidine (PINCH) protein and its prognostic importance in PMP. MATERIALS AND METHODS: Surgical specimens from 81 patients, classified according to the Ronnett et al histopathological classification were compared to a new system with four groups ranging from indolent to aggressive growth patterns. PINCH protein expression was analyzed and was related to clinical variables. RESULTS: The new four-group classification provided better prognostic information than the classification according to Ronnett et al. (p=0.04). Expression of the PINCH protein in the stroma was found in 83% of the cases and was associated with high tumor burden (p=0.002) and a poor prognosis (p=0.04). CONCLUSION: The proposed new PMP classification system may provide additional prognostic information. PINCH protein is expressed in PMP and has prognostic information.


Subject(s)
Adaptor Proteins, Signal Transducing/physiology , LIM Domain Proteins/physiology , Pseudomyxoma Peritonei/metabolism , Adult , Aged , Female , Humans , Male , Membrane Proteins/physiology , Middle Aged , Prognosis
6.
J Surg Res ; 169(2): 194-201, 2011 Aug.
Article in English | MEDLINE | ID: mdl-20338595

ABSTRACT

BACKGROUND: Matrix metalloproteinases (MMPs) and serine proteases are able to degrade the extracellular matrix (ECM) and modulate immune responses in the gastrointestinal tract. The purpose of this study was to investigate local proteolysis in perforated appendicitis and its association with the appendix perforation. MATERIALS AND METHODS: Biopsies were taken at the sites of perforation (n = 15) and with a gradually increased distance from it. The expression and distribution of MMP-1, -2, and -9, the tissue inhibitor of metalloproteinases type (TIMP-1), plasminogen activator inhibitor type1 (PAI-1), and urokinase plasminogen activator (uPA) were measured by ELISA. The distribution of MMP-9, TIMP-1, uPA, and PAI-1 in perforated, nonperforated, and uninflamed appendix was investigated by immunohistochemistry with monoclonal antibody technique. RESULTS: MMP-1 expression was highest close to the perforation and was gradually decreased in biopsies in more distal locations (P < 0.01). MMP-9 showed a similar pattern being highest at the sites of perforation (P < 0.05), while MMP-2 expression showed a trend in the opposite direction without statistically significance. The expression of TIMP-1 trended lower at the sites of perforation. PAI-1 was highest at the sites of perforation (P < 0.01) and the uPA expression was similarly elevated close to and at the perforation. CONCLUSIONS: These data indicate a key role of MMP in the pathogenesis of appendix perforation. A local imbalance between MMP-9 and the inhibitor TIMP-1 could potentially contribute to the tissue injury leading to an appendix perforation. The overexpression of PAI-1 at the sites of perforation may also contribute to tissue damage.


Subject(s)
Appendicitis/enzymology , Appendicitis/pathology , Appendix/enzymology , Appendix/pathology , Peptide Hydrolases/metabolism , Adolescent , Adult , Biopsy , Extracellular Matrix/enzymology , Extracellular Matrix/pathology , Female , Humans , Male , Matrix Metalloproteinase 9/metabolism , Middle Aged , Plasminogen Activator Inhibitor 1/metabolism , Retrospective Studies , Tissue Inhibitor of Metalloproteinase-1/metabolism , Young Adult
7.
Anticancer Res ; 30(9): 3727-30, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20944161

ABSTRACT

Uterine clear cell carcinoma (UCC) and uterine papillary serous carcinoma (UPSC) are rare entities that differ in clinical behavior from endometrial adenocarcinoma. Compared with endometrioid adenocarcinoma, they more often metastasize early and more commonly in the upper abdomen including the omentum. Treatment programs of UCC and UPSC at different stages vary and range from no adjuvant therapy in stage Ia to a wide variety of chemotherapies and radiotherapies in more advanced stages. This study presents the outcome of 109 patients with UCC or UPSC treated according to essentially the same treatment program from May 1993 to December 2004. Most patients were treated with a simple hysterectomy with no further adjuvant treatment. In stage Ia, 2/46 patients died of their disease and amongst all the stages, 30/109 patients died of their disease. These survival outcomes are comparable to or better than those presented previously.


Subject(s)
Adenocarcinoma, Clear Cell/mortality , Cystadenocarcinoma, Serous/mortality , Uterine Neoplasms/mortality , Adenocarcinoma, Clear Cell/pathology , Adenocarcinoma, Clear Cell/therapy , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Cystadenocarcinoma, Papillary/mortality , Cystadenocarcinoma, Papillary/pathology , Cystadenocarcinoma, Papillary/therapy , Cystadenocarcinoma, Serous/pathology , Cystadenocarcinoma, Serous/therapy , Female , Humans , Hysterectomy , Neoplasm Staging , Radiotherapy , Uterine Neoplasms/pathology , Uterine Neoplasms/therapy
8.
Scand J Gastroenterol ; 44(5): 579-84, 2009.
Article in English | MEDLINE | ID: mdl-19153874

ABSTRACT

OBJECTIVE: Serine proteases and the matrix metalloproteinases (MMPs) are key factors in the proteolytic cascade and participate in extracellular matrix (ECM) degradation. Fibrinolytic activators and inhibitors may have an effect on inflammatory cells, thereby modulating the inflammatory response. It is reasonable to assume that they may be implicated in the tissue injury in acute appendicitis that subsequently leads to appendix perforation. The purpose of this study was to investigate the expression and distribution of urokinase-type plasminogen activator (uPA) and plasminogen-activator inhibitor type 1 (PAI-1) in appendicitis. MATERIAL AND METHODS: Expression of uPA and expression of PAI-1 were measured in tissue specimens from patients with appendicitis (n=30) and in control specimens (n=9), using the quantitative ELISA technique. Distribution of enzymes was studied with immunohistochemistry. The uPA and PAI-1 levels in the subgroups of appendicitis and controls were compared. RESULTS: The overall expressions of uPA and PAI-1 were greater in appendicitis than in control specimens (p <0.001 and p<0.0001, respectively). Expressions of uPA and PAI-1 in phlegmonous (n=15), gangrenous (n=6) and perforated appendicitis (n=9) were all higher than those in controls (n=9), (p<0.01). Moreover, the PAI-1 level was elevated in perforated appendicitis compared with phlegmonous appendicitis (p<0.01). uPA staining was observed in connection with vascular endothelial cells and the serosa stained intensely in specimens from perforated appendicitis. CONCLUSIONS: The expression of uPA and especially the over-expression of PAI-1 seem to correlate to the progression of local inflammatory response in acute appendicitis.


Subject(s)
Appendicitis/pathology , Intestinal Mucosa/pathology , Plasminogen Activator Inhibitor 1/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Adult , Appendectomy , Appendicitis/blood , Appendicitis/surgery , Biopsy, Needle , Case-Control Studies , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Gene Expression Regulation , Humans , Immunohistochemistry , In Situ Hybridization , Inflammation Mediators/analysis , Inflammation Mediators/metabolism , Male , Middle Aged , Plasminogen Activator Inhibitor 1/genetics , Probability , RNA, Messenger/analysis , Reference Values , Sensitivity and Specificity , Serine Endopeptidases/genetics , Serine Endopeptidases/metabolism , Severity of Illness Index , Statistics, Nonparametric , Urokinase-Type Plasminogen Activator/genetics , Young Adult
9.
Pharmacol Res ; 58(3-4): 222-31, 2008.
Article in English | MEDLINE | ID: mdl-18812224

ABSTRACT

The aim of this study was to investigate the relevance of mouse ex vivo cultures as a first screening model for new therapeutic agents of Inflammatory Bowel Disease (IBD). Two murine models (dextran sodium sulphate (DSS)-induced colitis and Galphai2-deficient mice) and two anti-inflammatory agents (methyl-prednisolone and the proteasome inhibitor MG132) were evaluated. The in vivo effects of methyl-prednisolone were assessed in both models. Ex vivo colonic tissue from both mouse models were cultured in the presence or absence of the drugs and TaqMan Low-Density arrays were used to assess the regulation of inflammatory genes before and after drug treatment. Colitis induced a similar inflammatory gene profile in both mouse models in in vivo studies and in ex vivo cultures. The differences encountered reflected the different phases of colitis in the models, e.g. innate cytokine/chemokine profile in the DSS model and T cell related markers in Galphai2-deficient mice. After steroid treatment, a similar pattern of genes was suppressed in the two mouse models. We confirmed the suppression of inflammatory gene expression for IL-1beta, IL-6 and iNOS in ex vivo and in vivo colons from both mouse models by quantitative RT-PCR. Importantly, the inflammatory responses in the murine ex vivo culture system reflected the in vivo response in the inflamed colonic tissue as assessed by changes in inflammatory gene expression, suggesting that the murine culture system can be used for validation of future IBD therapies.


Subject(s)
Colitis/drug therapy , Inflammatory Bowel Diseases/drug therapy , Animals , Anti-Inflammatory Agents/therapeutic use , Cells, Cultured , Colitis/chemically induced , Colitis/genetics , DNA Primers , Dextran Sulfate , Female , GTP-Binding Protein alpha Subunits, Gi-Go/deficiency , GTP-Binding Protein alpha Subunits, Gi-Go/genetics , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/pathology , Interleukin-1beta/biosynthesis , Interleukin-6/biosynthesis , Leupeptins/pharmacology , Methylprednisolone/therapeutic use , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide Synthase Type II/biosynthesis , Organ Culture Techniques , Reverse Transcriptase Polymerase Chain Reaction
10.
Anticancer Res ; 28(2B): 1259-62, 2008.
Article in English | MEDLINE | ID: mdl-18505063

ABSTRACT

Tamoxifen is the most used adjuvant drug in breast cancer treatment. Its main action is as an anti-oestrogen, but in the endometrium of some patients it acts as an oestrogen. Some investigators have even reported an increased risk of developing endometrial carcinoma. The question of how to follow-up these patients and how to identify patients at risk of developing endometrial premalignant changes was investigated by the noninvasive ultrasound method. The follow-up of 292 patients from before the start of adjuvant treatment with tamoxifen and 94 without tamoxifen treatment was conducted at regular intervals. The changes in endometrial thickness as measured by ultrasound and histopathological changes are reported. A thicker endometrium was found in patients with receptor positive breast cancer even before the treatment with tamoxifen started. Cumulative increasing thickness was found during treatment and this thicker endometrium remained until almost 3 years after the end of treatment. If the endometrium was <3 mm after 3 months of treatment the probability that it would be thin after 5 years was high. An increased risk of developing endometrial carcinoma was found, however due to this regular follow-up the cancer was identified at an early stage.


Subject(s)
Breast Neoplasms/drug therapy , Endometrial Neoplasms/chemically induced , Endometrium/drug effects , Tamoxifen/adverse effects , Chemotherapy, Adjuvant , Endometrial Neoplasms/pathology , Endometrium/diagnostic imaging , Endometrium/pathology , Female , Follow-Up Studies , Humans , Middle Aged , Tamoxifen/administration & dosage , Ultrasonography
11.
Ups J Med Sci ; 112(1): 49-60, 2007.
Article in English | MEDLINE | ID: mdl-17578807

ABSTRACT

Patients with longstanding chronic ulcerative proctocolitis are at risk to develop colorectal cancer Conflicting views as regards surveillance, the indications for surgery and type of preventive procedure exist. For permanent prevention of cancer development complete removal of all potential malignant colorectal mucosa has to be done. Panprocto-colectomy with a conventional ileostomy or continent ileostomy removing all colorectal mucosa should therefore eliminate further risks of colorectal cancer. Colectomy and ileorectal anastomosis is a controversial issue. While many surgeons today are reluctant to use the technique, emphasising the persistent cancer risk, others consider the operation a viable alternative when used on a selective basis. The long-term risk of cancer in the rectal stump is the main strong argument . In restorative proctocolectomy, i.e. proctocolectomy with construction of an ileopouch anal anastomosis residual rectal mucosa is left behind irrespective of technique used and is therefore at risk for cancer development. Quite a few cancers have been reported to occur in these patients but controversy exists as regards the origin of these tumours but the risk for cancer development is very low. Biopsies from ileal pouches demonstrate various histopathological changes from nearly normal mucosa, to inflammation and atrophy, inflammatory cell changes, dysplasia as well as development of carcinoma. Grading of type and atypia is a challenge to reproduce and requires the participation of experienced gastrointestinal histopathologists.


Subject(s)
Colitis, Ulcerative/surgery , Colorectal Neoplasms/prevention & control , Colitis, Ulcerative/pathology , Colonoscopy , Colorectal Neoplasms/diagnosis , Digestive System Surgical Procedures , Humans
12.
Immunology ; 122(2): 199-209, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17490434

ABSTRACT

Galphai2-deficient mice, which spontaneously develop colitis, have previously been reported to have an increased frequency of mature, single positive thymocytes compared to wild-type mice. In this study we further characterized the intrathymic changes in these mice before and during overt colitis. Even before the onset of colitis, Galphai2(-/-) thymi weighed less and contained fewer thymocytes, and this was exacerbated with colitis development. Whereas precolitic Galphai2(-/-) mice had unchanged thymocyte density compared to Galphai2(+/-) mice of the same age, this was significantly decreased in mice with colitis. Thymic atrophy in Galphai2(-/-) mice involved mainly the cortex. Using a five-stage phenotypic characterization of thymocyte maturation based on expression of CD4, CD8, TCRalphabeta, CD69 and CD62L, we found that both precolitic and colitic Galphai2(-/-) mice had significantly increased frequencies of mature single-positive CD4(+) and CD8(+) medullary thymocytes, and significantly reduced frequencies and total numbers of immature CD4(+) CD8(+) double-positive thymocytes compared to Galphai2(+/-) mice. Furthermore, cortical and transitional precolitic Galphai2(-/-) thymocytes showed significantly reduced chemotactic migration towards CXCL12, and a trend towards reduced migration to CCL25, compared to wild-type thymocytes, a feature even more pronounced in colitic mice. This impaired chemotactic migration of Galphai2(-/-) thymocytes could not be reversed by increased chemokine concentrations. Galphai2(-/-) thymocytes also showed reduced expression of the CCL25 receptor CCR9, but not CXCR4, the receptor, for CXCL12. Finally, wild-type colonic lamina propria lymphocytes migrated in response to CXCL12, but not CCL25 and, as with thymocytes, the chemokine responsiveness was significantly reduced in Galphai2(-/-) mucosal lymphocytes.


Subject(s)
Chemotaxis, Leukocyte/immunology , Colitis/immunology , GTP-Binding Protein alpha Subunit, Gi2/deficiency , T-Lymphocyte Subsets/immunology , Thymus Gland/immunology , Animals , Chemokine CXCL12 , Chemokines/immunology , Chemokines, CXC/immunology , Colitis/pathology , Colon/immunology , Disease Models, Animal , Disease Progression , Female , GTP-Binding Protein alpha Subunit, Gi2/genetics , Intestinal Mucosa/immunology , Lymphocyte Count , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Organ Size , Receptors, CCR , Receptors, CXCR4/metabolism , Receptors, Chemokine/metabolism , Thymus Gland/pathology
14.
Ups J Med Sci ; 111(2): 227-30, 2006.
Article in English | MEDLINE | ID: mdl-16961178

ABSTRACT

Malacoplakia is a granulomatous disease with a histiocytic infiltrate containing calcified structures called Michaelis-Gutmann bodies. These structures are considered to represent an abnormal response to infection involving defective lysosomes and abnormal microbubular assembly. The disease most frequently involves urinary and genital tracts, but has also been described from most other organs. Here we present the first case of malacoplakia only involving the vas deferens.


Subject(s)
Genital Neoplasms, Male/ultrastructure , Granuloma/pathology , Malacoplakia/pathology , Semen , Vas Deferens/ultrastructure , Adult , Genital Neoplasms, Male/surgery , Granuloma/surgery , Humans , Malacoplakia/surgery , Male , Vas Deferens/surgery , Vasectomy
15.
Clin Colorectal Cancer ; 5(5): 344-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16512993

ABSTRACT

BACKGROUND: The aim of the study was to investigate the influence of methylenetetrahydrofolate reductase (MTHFR) gene expression levels and MTHFR polymorphism C677T on the outcome of patients with colorectal cancer (CRC). Furthermore, we wanted to evaluate the interaction between MTHFR and thymidylate synthase (TS) and folylpolyglutamate synthase (FPGS) and to investigate the impact of folate concentration on patients with CRC with different MTHFR genotypes. PATIENTS AND METHODS: The frequency of MTHFR polymorphism C677T was determined (n = 147), and gene expression levels of MTHFR, TS, and FPGS were quantified with real-time polymerase chain reaction (n = 157). Reduced folates in tissue were measured with a binding assay (n = 40). RESULTS: We observed a significantly lower concentration of tetrahydrofolate (THF) in patients with CT or TT genotypes compared with patients having the CC genotype. Twenty-six patients with Dukes A to C tumors who had not been subjected to chemotherapy relapsed. Out of these, 18 had CT or TT genotypes, and only 8 had the CC genotype (P = 0.045). Furthermore, 75 patients did not relapse, and out of these, 35 had CT or TT genotypes, and 40 had the CC genotype. The relative gene expression level of MTHFR in patients subgrouped by CC and CT or TT genotypes was significantly lower in carcinomas compared with adjacent mucosa (P < 0.0001 and P < 0.0001, respectively). A significant difference in MTHFR expression level was also observed according to MTHFR genotype in the tumor but not in adjacent mucosa. The MTHFR gene expression level in mucosa was a prognostic parameter independent of the clinicopathologic factors with regard to survival for patients with MTHFR C677T mutation. CONCLUSION: Our results showed that it is possible to identify patients with CRC with a higher risk for relapse. Furthermore, patients with a mutant genotype in combination with low MTHFR expression have a poor clinical outcome.


Subject(s)
Carcinoma/metabolism , Carcinoma/mortality , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/mortality , Intestinal Mucosa/metabolism , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma/genetics , Colorectal Neoplasms/genetics , Female , Folic Acid/genetics , Folic Acid/metabolism , Gene Expression , Humans , Male , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Middle Aged , RNA, Messenger/metabolism , Survival Rate
16.
Inflamm Bowel Dis ; 11(11): 997-1005, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16239846

ABSTRACT

To elucidate the potential cell population(s) involved in the induction of colitis in inhibitory G protein Galphai2(-/-) mice, Galphai2-deficient or competent bone marrow or splenic and mesenteric lymph node (MLN) T cells were transferred into immunodeficient mice. The mice were followed up to 23 weeks after transfer, recording changes in body weight. Colitis was graded on hematoxylin and eosin-stained colonic tissue, and production of serum interleukin-18 and colon-derived interferon-gamma was measured using ELISA. After adoptive transfer of Galphai2(-/-) bone marrow, severe colitis developed in irradiated wild type recipients, whereas irradiated Galphai2(-/-) mice increased their life span more than 3 times after transfer of wild type bone marrow, accompanied by significant amelioration of colitis. Neither purified Galphai2(-/-) CD4(+), nor CD8(+) splenic or MLN-derived T cells could induce colitis in recombination-activating gene V(RAG) 2(-/-) recipient mice, whereas transfer of splenic Galphai2(-/-) CD3(+) T cells induced severe colitis. In contrast, transfer of Galphai2(-/-) CD3(+) T cells from the MLN caused only minor histopathological changes in the intestinal mucosa. Finally, serum levels of interleukin-18 and interferon-gamma production from colonic tissue cultures correlated well with disease severity. Our results show that bone marrow transplantation can prolong the life of Galphai2(-/-) mice and ameliorate intestinal inflammation. Splenic CD4(+) or CD8(+) T cells on their own were poor inducers of colitis, whereas the combination of both was highly involved in the induction of intestinal inflammation. Furthermore, we show that the tissue origin of CD3(+) T cells is critical for their potency to induce colitis.


Subject(s)
Colitis/immunology , Colitis/physiopathology , GTP-Binding Protein alpha Subunit, Gi2/genetics , GTP-Binding Protein alpha Subunit, Gi2/physiology , T-Lymphocytes/immunology , Animals , CD3 Complex , Cytokines/blood , Enzyme-Linked Immunosorbent Assay , Female , Immunocompetence , Lymph Nodes/cytology , Male , Mice , Mice, Knockout , Spleen/cytology
17.
Cancer Detect Prev ; 29(4): 348-55, 2005.
Article in English | MEDLINE | ID: mdl-16122883

ABSTRACT

BACKGROUND: Cellular folate deficiency leads to DNA strand breaks, mutations, and aberrant methylation and might be a risk factor for colorectal cancer (CRC). The putative tumor suppressor gene deleted in colorectal carcinoma (DCC) is one of several genes the expression of which seems to be affected by the folate concentration at the tissue level. Decreased expression of DCC may be caused by LOH or hypermethylation, i.e. by events that might be linked to folate deficiency. The purpose of this study was to analyze if the folate level and the gene expression levels of reduced folate carrier (RFC-1) and folylpolyglutamate synthase (FPGS) had impact on the expression of DCC splice variants. METHODS: Quantification of RFC-1 and FPGS expression in mucosa of 53 CRC patients was performed using real-time PCR whereas DCC splicing variants were detected by automated capillary gel electrophoresis. Total reduced folate concentration was measured with the FdUMP-binding assay (n = 22). RESULTS: Significantly higher expression levels of RFC-1 (p = 0.026) and FPGS (p = 0.05) were found in mucosa expressing the splice variant DCC342 compared to mucosa that did not. Furthermore, multivariate analysis showed that RFC-1 and FPGS (r = 0.49, p = 0.01) as well as folate and RFC-1 (r = 0.56, p = 0.023) were correlated only in mucosa expressing DCC342. CONCLUSIONS: In conclusion, the present study points to a potential influence of folates in regulating DCC expression at multiple levels involving post-transcriptional pathways. The results may provide a basis for a detailed investigation of molecular mechanisms involved in folate regulation of DCC expression.


Subject(s)
Adenocarcinoma/genetics , Alternative Splicing , Colorectal Neoplasms/genetics , Intestinal Mucosa/chemistry , Membrane Transport Proteins/genetics , Peptide Synthases/genetics , RNA, Neoplasm/genetics , Adenocarcinoma/chemistry , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Colorectal Neoplasms/chemistry , Colorectal Neoplasms/pathology , Female , Folic Acid Deficiency/genetics , Gene Expression Regulation, Neoplastic , Genes, DCC/genetics , Humans , Male , Membrane Transport Proteins/analysis , Middle Aged , Molecular Sequence Data , Multivariate Analysis , Peptide Synthases/analysis , Reduced Folate Carrier Protein , Reverse Transcriptase Polymerase Chain Reaction , Sweden
18.
Eur J Immunol ; 35(8): 2274-83, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16052630

ABSTRACT

Targeted deletion of the heterotrimeric G protein, Galphai2, in mice induces lethal colitis closely resembling ulcerative colitis. In chronic colitis, migration of circulating leukocytes into the intestinal mucosa is partially dependent on alpha4 integrins. In previous studies, short-term administration of anti-alpha4 integrin antibodies has been shown to attenuate intestinal inflammation, and here we elucidate the effect of long-term administration of anti-alpha4 integrin antibodies on colitis in Galphai2(-/- )mice. Long-term blockade of alpha4 integrin significantly increased the severity of colitis in Galphai2(-/-) mice. The inflammation was confined to the colon, associated with increased cancer in situ, destruction of crypt architecture, and increased production of IL-1beta, TNF-alpha and IFN-gamma. Blockade of alpha4 integrin reduced the recruitment of activated T cells to the small intestine. In strong contrast, there were significantly higher numbers of activated T cells in the colonic lamina propria and epithelium, most probably due to in situ proliferation. Furthermore, treatment with alpha4 integrin antibodies induced decreased levels of total IgA and IgG in sera, whereas total IgM levels were unchanged. These new findings may have implications in the understanding of the progression of chronic intestinal inflammation.


Subject(s)
Antibodies, Blocking/adverse effects , Antibodies, Monoclonal/adverse effects , Colitis/immunology , GTP-Binding Protein alpha Subunits, Gi-Go/deficiency , Inflammatory Bowel Diseases/therapy , Integrin alpha4/immunology , Proto-Oncogene Proteins/deficiency , Animals , Antibodies, Blocking/therapeutic use , Antibodies, Monoclonal/therapeutic use , Colitis/pathology , Colon/drug effects , Colon/immunology , Disease Models, Animal , Female , GTP-Binding Protein alpha Subunit, Gi2 , GTP-Binding Protein alpha Subunits, Gi-Go/genetics , Immunoglobulin A/blood , Immunoglobulin G/blood , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/immunology , Lymphoid Tissue/drug effects , Lymphoid Tissue/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Proto-Oncogene Proteins/genetics , Spleen/drug effects , Spleen/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Time Factors
19.
Ann Surg ; 242(1): 49-54, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15973101

ABSTRACT

OBJECTIVE: To evaluate risk factors for dysplasia and adenocarcinoma development in nondysplastic Barrett mucosa. SUMMARY BACKGROUND DATA: The risk for patients with Barrett esophagus to develop esophageal adenocarcinoma is low, and most patients undergoing surveillance will not develop malignancy. Identification of risk factors may allow for more rational surveillance programs in which patients are stratified according to their individual risk of progressing to dysplasia and invasive adenocarcinoma. METHODS: The development of dysplasia and esophageal adenocarcinoma was studied during long-term endoscopic and histologic surveillance in 140 patients with Barrett esophagus free from dysplasia. Risk factors for progression to dysplasia and adenocarcinoma were evaluated. RESULTS: Median follow-up was 5.8 years. Forty-four patients (31.4%) developed low-grade dysplasia and 7 patients (5%) developed high-grade dysplasia or esophageal adenocarcinoma. Dysplasia development was significantly less common after antireflux surgery compared with conventional medical therapy. Low-grade dysplasia (relative risk = 5.5; 95% confidence interval, 1.1-28.6) and long duration of reflux symptoms (relative risk = 1.3; 95% confidence interval, 1.2-1.7) were independently associated with an increased risk of developing high-grade dysplasia or esophageal adenocarcinoma. CONCLUSIONS: Successful antireflux surgery protects the Barrett mucosa from developing high-grade dysplasia and esophageal adenocarcinoma, possibly by better control of reflux of gastric contents. Low-grade dysplasia is the only clinically useful risk factor that permits stratification of the surveillance intervals according to the risk of the individual patient.


Subject(s)
Adenocarcinoma/pathology , Barrett Esophagus/pathology , Esophageal Neoplasms/pathology , Precancerous Conditions/pathology , Adenocarcinoma/epidemiology , Adenocarcinoma/surgery , Adult , Age Distribution , Aged , Barrett Esophagus/epidemiology , Barrett Esophagus/surgery , Biopsy, Needle , Disease Progression , Esophageal Neoplasms/epidemiology , Esophageal Neoplasms/surgery , Esophagoscopy/methods , Female , Humans , Immunohistochemistry , Incidence , Male , Middle Aged , Precancerous Conditions/surgery , Probability , Prognosis , Proportional Hazards Models , Prospective Studies , Registries , Risk Factors , Sex Distribution , Statistics, Nonparametric
20.
Ups J Med Sci ; 110(3): 233-6, 2005.
Article in English | MEDLINE | ID: mdl-16454160

ABSTRACT

Sertoli-Leydig cell tumours are rare sex stromal tumours with an incidence of < 0.5% of all ovarian tumours. Most frequently this tumour occurs in young women with a history of amenorrhoea, hirsutism and lowered pitch. Here, we report on a woman with IRS, postmenopausal virilization and increased testosterone levels due to a Sertoli-Leydig cell tumour. This is the first case to suggest an association between IRS and Sertoli-Leydig cell tumours. Furthermore, we highlight the difficulties in detecting this ovarian tumour with sonography.


Subject(s)
Insulin Resistance , Postmenopause/physiology , Sertoli-Leydig Cell Tumor/complications , Sertoli-Leydig Cell Tumor/pathology , Female , Humans , Immunohistochemistry , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...